Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2026)

Anaptysbio's Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $65.9 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 28.07% year-over-year to $65.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.9 million (down 28.07% YoY) and the FY2025 annual result came in at $87.9 million, down 32.62% from the prior year.
• Total Non-Current Liabilities was $65.9 million for Q1 2026 at Anaptysbio, down from $87.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $583.5 million in Q3 2022 and bottomed at $3.9 million in Q2 2025.
• A 5-year average of $180.9 million and a median of $141.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Peak annual rise in Total Non-Current Liabilities reached 4.16% in 2025, while the deepest fall reached 94.05% in 2025.
• Anaptysbio's Total Non-Current Liabilities stood at $306.0 million in 2022, then plunged by 53.73% to $141.6 million in 2023, then dropped by 7.89% to $130.4 million in 2024, then tumbled by 32.62% to $87.9 million in 2025, then decreased by 24.95% to $65.9 million in 2026.
• Business Quant data shows ANAB's Total Non-Current Liabilities at $65.9 million in Q1 2026, $87.9 million in Q4 2025, and $21.3 million in Q3 2025.